

Resource Summary Report

Generated by [dkNET](#) on Sep 17, 2026

NUGC-3

RRID:CVCL_1612

Type: Cell Line

Proper Citation

RRID:CVCL_1612

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1612

Proper Citation: RRID:CVCL_1612

Description: Cell line NUGC-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Gastric adenocarcinoma

Defining Citation: [PMID:1370612](#), [PMID:1778766](#), [PMID:3172586](#), [PMID:3325673](#), [PMID:9290701](#), [PMID:15723654](#), [PMID:15767549](#), [PMID:19132987](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24807215](#), [PMID:25343454](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29435981](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: JFCR45 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NUGC-3

Synonyms: NUGC3, NU-GC-3, Nagoya University-Gastric Cancer-3

Cross References: BTO:BTO_0002597, CLO:CLO_0037144, EFO:EFO_0006702, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:397, BioSample:SAMN03473123, BioSample:SAMN10988359, cancercellines:CVCL_1612, Cell_Model_Passport:SIDM00572, CGH-DB:134-1, ChEMBL-Cells:ChEMBL3307562,

ChEMBL-Targets:CHEMBL614208, Cosmic:801341, Cosmic:877046, Cosmic:908455, Cosmic:918499, Cosmic:968351, Cosmic:1187288, Cosmic:1518256, Cosmic:1995599, Cosmic:2484968, Cosmic:2807638, Cosmic-CLP:908455, DepMap:ACH-000911, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:908455, GEO:GSM552367, GEO:GSM827405, GEO:GSM828828, GEO:GSM844666, GEO:GSM887462, GEO:GSM888542, GEO:GSM1374776, GEO:GSM1670287, IARC_TP53:973, JCRB:JCRB0822, LiGeA:CCLE_449, LINCX_LDP:LCL-1887, PharmacDB:NUGC3_1173_2019, PRIDE:PXD030304, Progenetix:CVCL_1612, PubChem_Cell_line:CVCL_1612, Wikidata:Q54931160

ID: CVCL_1612

Record Creation Time: 20220427T221350+0000

Record Last Update: 20260913T005634+0000

Ratings and Alerts

No rating or validation information has been found for NUGC-3.

No alerts have been found for NUGC-3.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kang M, et al. (2026) Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. *Molecular cancer therapeutics*, 25(5), 814.

Pan G, et al. (2026) MTSS1-dependent ubiquitin modifications mediated by FBXO44 remodel the actin cytoskeleton to promote gastric cancer progression. *Molecular cancer*, 25(1).

Cui X, et al. (2026) KYNU in Gastric Cancer Cells Promotes Tumor Progression by Influencing Macrophage Polarization Via PF4. *Cancer science*.

Zhang P, et al. (2026) SKA2 promotes gastric cancer progression by regulating glutathione metabolism. *iScience*, 29(4), 115202.

Fan W, et al. (2025) Ribosomal RNA transcription regulates splicing through ribosomal protein RPL22. *Cell chemical biology*, 32(7), 908.

Puzio-Kuter AM, et al. (2025) Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator. *Cancer discovery*, 15(6), 1159.

- Sasahara M, et al. (2024) Therapeutic antibody targeting natriuretic peptide receptor 1 inhibits gastric cancer growth via BCL-2-mediated intrinsic apoptosis. *International journal of cancer*, 154(7), 1272.
- Yonemura A, et al. (2024) Mesothelial cells with mesenchymal features enhance peritoneal dissemination by forming a protumorigenic microenvironment. *Cell reports*, 43(1), 113613.
- Wang SF, et al. (2024) Mitochondrial dysfunction decreases cisplatin sensitivity in gastric cancer cells through upregulation of integrated stress response and mitokine GDF15. *The FEBS journal*, 291(6), 1131.
- Nakayama T, et al. (2023) Inhibition of cancer cell-platelet adhesion as a promising therapeutic target for preventing peritoneal dissemination of gastric cancer. *Oncology letters*, 26(6), 538.
- Sahgal P, et al. (2023) Replicative stress in gastroesophageal cancer is associated with chromosomal instability and sensitivity to DNA damage response inhibitors. *iScience*, 26(11), 108169.
- Zhang W, et al. (2022) A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(23), 5190.
- Tanaka H, et al. (2022) Transcriptomic profiling on localized gastric cancer identified CPLX1 as a gene promoting malignant phenotype of gastric cancer and a predictor of recurrence after surgery and subsequent chemotherapy. *Journal of gastroenterology*, 57(9), 640.
- Umeda S, et al. (2022) Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells. *Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association*, 25(3), 558.
- Abe H, et al. (2021) Virus-host interactions in carcinogenesis of Epstein-Barr virus-associated gastric carcinoma: Potential roles of lost ARID1A expression in its early stage. *PloS one*, 16(9), e0256440.
- Li F, et al. (2021) Identification of ARGLU1 as a potential therapeutic target for gastric cancer based on genome-wide functional screening data. *EBioMedicine*, 69, 103436.
- Yasuda T, et al. (2021) Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination. *Cell reports*, 34(8), 108779.
- Sugimoto A, et al. (2021) EMMPRIN in extracellular vesicles from peritoneal mesothelial cells stimulates the invasion activity of diffuse-type gastric cancer cells. *Cancer letters*, 521, 169.
- Sakai H, et al. (2021) Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer. *Clinical and translational medicine*, 11(6), e454.